The objective of this study is to determine if pooled buffy coat-derived pathogen reduced plasma-stored platelet concentrates are non-inferior compared to plasma-stored platelet concentrates in terms of WHO bleeding complications in hemato-oncological patients with thrombocytopenia.
Currently some pathogen-reduced platelet products (PR-PCs) have passed phase III studies, are in progress or can be expected in the near future. At present some transfusion centers throughout Europe have implemented PR-PCs, but as yet PR-PCs are not formally accepted as a standard product that should be applied nation-wide. Because many uncertainties currently exist on the "optimal" platelet product, it is in the interest of patients, health care providers and the transfusion provider (Sanquin) to decide on evidence. With all the current safety measures remaining in place, pathogen reduction provides a safety benefit by reducing the number of transfusions of platelet concentrates contaminated with bacteria, but which were missed by the screening method. In the Dutch situation, morbidity is estimated to be 1:14,000 platelet concentrates \[Te Boekhorst, Transfusion 2005\]. In this publication, two cases of transmission of B. cereus by a platelet transfusion are reported, where both patients experience a life-threatening sepsis, but recover eventually. Cases of bacterial transmission however often go unnoted, so a frequency as low as 1:130,000 has been reported \[Dumont, Transfusion 2010\]. The same is true for mortality; this value ranges from 1:50,000 to 1:500,000. A more precautionary benefit is protection against known and unknown pathogens. It is difficult to estimate the actual risk, and consequently to estimate the benefit for the patient. While in The Netherlands no epidemics have occurred against which no screening tests could be developed, including Q-fever, there is a small but real risk that an epidemic can wipe out the blood supply in a country. This has happened in La Réunion, where an epidemic of chikungunya virus urged import of blood products from abroad, followed by rapid introduction of a pathogen reduction technology to ensure the blood supply \[Rasongles, Transfusion 2009\]. An outbreak of this virus in Italy resulted in suspension of blood collections in an affected area, which led to a low blood inventory as well as a reduced delivery of plasma to fractionation institutes. Appreciating the difficulties of extrapolating in vitro tests towards in vivo efficacy, platelet products should be tested in clinical trials. Of note, radiolabeling techniques in volunteers as required by the FDA, are not used in the Netherlands. For major product variations in the Netherlands, investigators depend on studies in patients. Extending storage for logistic purposes, combined with maintaining or even improving the safety of platelet products, and maintaining clinical efficacy are the main features in the development of new platelet products. In this study protocol, the aim is to investigate transfusion efficacy of two different platelet products: plasma-PCs, and pathogen-reduced (PR)-plasma-PCs, combining extended storage with or without treatment with a photochemical pathogen reduction technique. Prior to the start of the clinical study an in vitro study of the product has been performed, showing that the study product meets the current in vitro quality requirements for release for transfusion. However, on site implementation validation still has to take place. Refractoriness to platelet transfusions and bleeding complications are the main clinical problems in intensively treated hemato-oncological patients and are essential endpoints for transfusion studies as well. In this trial, bleeding will be scored according to the World Health Organization (WHO) scale as a primary endpoint. Refractoriness is defined as a 1-hour CCI \<7.5 and/or a 24-hour CCI \<4.5 after ABO compatible platelet transfusions on at least two successive occasions. Known causes of non-alloimmune refractoriness are included in this trial because for the purpose of generalization, relevant to develop a national product, testing transfusion efficacy of new platelet products should imply all patients in need of a preventive support with platelet transfusions. The 1- and 24-hour CCI are commonly used to evaluate platelet transfusions and, albeit not without discussion, currently the platelet count is the only parameter in trigger-based transfusion policy. The ratio of both the 1-hour and 24-hour CCI mirrors both platelet recovery immediately after transfusion as the 1-hour CCI, and platelet survival one day after transfusion as the 24-hour CCI. Other secondary clinical endpoints of the trial will be transfusion requirement (red cells and platelets), transfusion interval to next transfusion and adverse reactions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
567
Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.
Platelet concentrates stored in plasma
McMaster University
Hamilton, Canada
Kingston General Hospital
Kingston, Canada
London Health Sciences Centre
London, Canada
Ottawa Hospital
Ottawa, Canada
Percentage of patients with WHO grade ≥ 2 bleeding complications
Any WHO grade ≥ 2 bleeding event, as determined by daily assessment of bleeding symptoms, and documentation of any red blood cell transfusions to treat bleeding
Time frame: Transfusion episode (from the day of the first on-study transfusion until study completion), an average of 20 days
1 and 24 hour count increment
Time frame: 1 and 24 hours post-transfusion
1 and 24 hour corrected count increment (CCI)
Time frame: 1 and 24 hours post-transfusion
(1+24 hour CCI)/2
Time frame: 1 and 24 hours post-transfusion
Adverse transfusion reactions
All transfusion-associated side effects observed within 6 hours after platelet transfusion
Time frame: On-study episode (from the day of randomization until study completion), an average of 25 days
Total transfusion requirement of red cells and platelets
Number of occurrences of a platelet transfusion or a red cell transfusion among subjects who have had at least one platelet transfusion
Time frame: Transfusion episode (from the day of the first on-study transfusion until study completion), an average of 20 days
Platelet transfusion interval
Time in hours between the last and first occurrence of a platelet transfusion, divided by the number of platelet transfusion occurrences minus 1, among subjects who have had at least two platelet transfusions
Time frame: Transfusion episode (from the day of the first on-study transfusion until study completion), an average of 20 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Sunnybrook Health Sciences Centre
Toronto, Canada
Leiden University Medical Center
Leiden, Netherlands
Maastricht University Medical Center
Maastricht, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
Haga Ziekenhuis
The Hague, Netherlands
Haukeland University Hospital
Bergen, Norway
Rate of HLA allo-immunization
Time frame: From the day of randomization until 56 days after randomization
In vitro quality markers related with the 1-hour or 24-hour CCI
Time frame: 1 and 24 hours post-transfusion
Clinical factors interacting on primary endpoint, including in vivo variables of immunological responses; and of hemostasis in the recipients after transfusion as compared prior to transfusion.
Severity of the WHO bleeding grade as determined by daily assessment of bleeding symptoms, related to the level of circulating HLA allo antibodies as determined in a blood sample collected every week during the on-study episode; severity of the WHO bleeding grade as determined by daily assessment of bleeding symptoms at the day of occurrence of a platelet transfusion as compared to the day after the occurrence of a platelet transfusion
Time frame: Transfusion episode (from the day of the first on-study transfusion until study completion), an average of 20 days